DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Epirubicin (Epirubicin) - Disability - Suspected Cause - Side Effect Reports

 
 



Index of reports > Disability (14)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Epirubicin disability. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Epirubicin side effects in female

Reported by a individual with unspecified qualification from Denmark on 2012-06-15

Patient: female

Reactions: Thrombosis, Pain in Extremity, Thrombectomy, LEG Amputation

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer
    Start date: 2010-12-07

Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2010-12-07

Taxotere
    Indication: Breast Cancer
    Start date: 2010-12-07

Other drugs received by patient: Clemastine Fumarate



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-05-21

Patient: female

Reactions: Maternal Exposure During Pregnancy, Cardiomyopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Epirubicin
    Indication: Breast Cancer



Possible Epirubicin side effects in female

Reported by a consumer/non-health professional from South Africa on 2012-04-16

Patient: female, weighing 56.0 kg (123.2 pounds)

Reactions: Injection Site Extravasation, Alopecia, Thrombophlebitis

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Taxotere
    Indication: Chemotherapy
    Start date: 2008-08-27
    End date: 2008-10-27

Fluorouracil
    Indication: Chemotherapy
    Start date: 2008-07-11
    End date: 2008-07-31

Epirubicin
    Indication: Chemotherapy
    Start date: 2008-07-11
    End date: 2008-07-31

Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2008-07-11
    End date: 2008-07-31



Possible Epirubicin side effects in 53 year old female

Reported by a lawyer from Denmark on 2012-03-29

Patient: 53 year old female

Reactions: Thrombosis, Pain in Extremity, Thrombectomy, LEG Amputation

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Taxotere
    Indication: Breast Cancer
    Start date: 2010-12-07

Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2010-12-07

Epirubicin
    Indication: Breast Cancer
    Start date: 2010-12-07

Other drugs received by patient: Clemastine



Possible Epirubicin side effects in female

Reported by a lawyer from Denmark on 2012-03-27

Patient: female

Reactions: Thrombosis, Pain in Extremity, LEG Amputation, Thrombectomy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Taxotere
    Indication: Breast Cancer
    Start date: 2010-12-07

Epirubicin
    Indication: Breast Cancer
    Start date: 2010-12-07

Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2010-12-07

Other drugs received by patient: Clemastine Fumarate



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-03-20

Patient: female

Reactions: Blood Iron Decreased, Alopecia, Hair Growth Abnormal, Hair Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Femara
    Dosage: unk
    Administration route: Oral
    Start date: 2011-04-01

Epirubicin
    Dosage: unk
    Start date: 2010-10-14
    End date: 2010-11-25

Fluorouracil
    Dosage: unk
    Start date: 2010-10-14
    End date: 2010-11-25

Cyclophosphamide
    Dosage: unk
    Start date: 2010-10-14
    End date: 2010-11-25

Taxotere
    Dosage: unk
    Start date: 2010-12-16
    End date: 2011-01-27



Possible Epirubicin side effects in female

Reported by a lawyer from Germany on 2012-03-05

Patient: female, weighing 81.0 kg (178.2 pounds)

Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Papilloedema, Visual Evoked Potentials Abnormal

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Epirubicin
    Start date: 2009-07-14

Docetaxel
    Dosage: unk
    End date: 2009-09-15

Femara
    Dosage: 2.5 mg, daily
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2009-11-03
    End date: 2009-12-09

Docetaxel
    Dosage: unk
    Start date: 2009-08-25

Docetaxel
    Start date: 2009-08-04

Docetaxel
    Dosage: unk
    End date: 2009-10-13

Cyclophosphamide
    End date: 2009-10-01

Other drugs received by patient: Doxycycline; Radiation; Factor Xiii (Fibrin Stabilising Factor); Aspirin



Possible Epirubicin side effects in female

Reported by a lawyer from Germany on 2012-03-02

Patient: female, weighing 81.0 kg (178.2 pounds)

Reactions: Amblyopia Strabismic, Optic Atrophy, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Docetaxel
    Start date: 2009-08-04

Docetaxel
    Dosage: unk
    End date: 2009-10-13

Docetaxel
    Dosage: unk
    Start date: 2009-08-25

Femara
    Dosage: 2.5 mg, daily
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2009-11-03
    End date: 2009-12-09

Epirubicin
    Start date: 2009-07-14

Docetaxel
    Dosage: unk
    End date: 2009-09-15

Cyclophosphamide
    End date: 2009-10-01

Other drugs received by patient: Radiation; Factor Xiii (Fibrin Stabilising Factor); Aspirin; Doxycycline



Possible Epirubicin side effects in 55 year old female

Reported by a physician from Germany on 2011-11-25

Patient: 55 year old female, weighing 75.0 kg (165.0 pounds)

Reactions: Endometrial Cancer

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Fluorouracil

Epirubicin

Cyclophosphamide

Trastuzumab
    Start date: 2010-10-27

Docetaxel



Possible Epirubicin side effects in 55 year old female

Reported by a physician from Germany on 2011-11-22

Patient: 55 year old female, weighing 75.0 kg (165.0 pounds)

Reactions: Endometrial Cancer

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Fluorouracil

Docetaxel

Cyclophosphamide

Trastuzumab
    Start date: 2010-10-27

Epirubicin



Possible Epirubicin side effects in female

Reported by a consumer/non-health professional from Denmark on 2011-11-22

Patient: female, weighing 53.0 kg (116.6 pounds)

Reactions: Pain, Paralysis, Myalgia, Fatigue, Coordination Abnormal, Peripheral Motor Neuropathy, Back Pain, Condition Aggravated, Hypoaesthesia, Paraesthesia, Dysgeusia, Burning Sensation, Arthralgia, Sensory Disturbance, Asthenia, Neuritis, Walking Disability, Disability

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer
    Start date: 2009-10-19

Epirubicin
    Start date: 2009-11-01

Taxotere
    Start date: 2009-09-28
    End date: 2009-09-28

Taxotere
    Indication: Breast Cancer
    Start date: 2009-09-28
    End date: 2009-09-28

Other drugs received by patient: Cyclophosphamide; Cyclophosphamide; Neulasta



Possible Epirubicin side effects in female

Reported by a lawyer from Germany on 2011-10-24

Patient: female, weighing 81.0 kg (178.2 pounds)

Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Femara
    Dosage: 2.5 mg, daily
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2009-11-03
    End date: 2009-12-09

Epirubicin
    Dosage: unk
    Start date: 2009-07-14

Docetaxel
    Dosage: unk
    End date: 2009-09-15

Cyclophosphamide
    Dosage: unk
    End date: 2009-10-01

Docetaxel
    Dosage: unk
    Start date: 2009-08-25

Docetaxel
    Dosage: unk
    Start date: 2009-08-04

Docetaxel
    Dosage: unk
    End date: 2009-10-13

Other drugs received by patient: Aspirin; Doxycycline; Factor Xiii (Fibrin Stabilising Factor); Radiation



Possible Epirubicin side effects in female

Reported by a pharmacist from Germany on 2011-10-24

Patient: female, weighing 81.0 kg (178.2 pounds)

Reactions: Amblyopia Strabismic, Optic Atrophy, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Papilloedema, Visual Evoked Potentials Abnormal

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    End date: 2009-10-01

Docetaxel
    Dosage: unk
    Start date: 2009-08-04

Docetaxel
    Dosage: unk
    End date: 2009-10-13

Docetaxel
    Dosage: unk
    End date: 2009-09-15

Epirubicin
    Dosage: unk
    Start date: 2009-07-14

Docetaxel
    Dosage: unk
    Start date: 2009-08-25

Femara
    Dosage: 2.5 mg, daily
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2009-11-03
    End date: 2009-12-09

Other drugs received by patient: Radiation; Aspirin; Factor Xiii (Fibrin Stabilising Factor); Doxycycline



Possible Epirubicin side effects in female

Reported by a pharmacist from Germany on 2011-10-24

Patient: female, weighing 81.0 kg (178.2 pounds)

Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Docetaxel
    Dosage: unk
    Start date: 2009-08-25

Docetaxel
    Dosage: unk
    End date: 2009-10-13

Cyclophosphamide
    Dosage: unk
    End date: 2009-10-01

Femara
    Dosage: 2.5 mg, daily
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2009-11-03
    End date: 2009-12-09

Epirubicin
    Dosage: unk
    Start date: 2009-07-14

Docetaxel
    Dosage: unk
    End date: 2009-09-15

Docetaxel
    Dosage: unk
    Start date: 2009-08-04

Other drugs received by patient: Factor Xiii (Fibrin Stabilising Factor); Doxycycline; Aspirin; Radiation

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014